Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
|Articles|August 19, 2022
Daily Medication Pearl: Kcentra [Prothrombin Complex Concentrate (Human)]
Author(s)Saro Arakelians, PharmD
Kcentra is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adult patients with acute major bleeding.
Advertisement
Medication Pearl of the Day: Kcentra [Prothrombin Complex Concentrate (Human)]
Indication: Kcentra [prothrombin complex concentrate (human)], is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (e.g., warfarin) therapy in adult patients with acute major bleeding.
Insight:
- Dosing: 20 to 50 units/kg, do not exceed 2500 to 5000 units.
- Dosage forms: Kcentra is available as a single-use vial containing coagulation factors II, VII, IX and X, and antithrombotic proteins C and S as a lyophilized concentrate.
- Adverse events: The most common adverse reactions (frequency ≥2.8%) observed in subjects receiving Kcentra were headache, nausea/vomiting, arthralgia, and hypotension.
- Mechanism of action: Kcentra contains the vitamin K-dependent coagulation factors II (FII), VII (FVII), IX (FIX), and X (FX), together known as the prothrombin complex, and the antithrombotic protein C and protein S. If the patient has an acquired coagulation factor deficiency where one or more of the vitamin K-dependent coagulation factors are deficient, bleeding may occur.
Advertisement
Related to this article
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
ENDURANCE trial finds fixed 2-year lenalidomide maintenance matches continuous therapy for standard-risk multiple myeloma survival, guiding oncology pharmacists on MM regimen toxicity.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Advertisement
Advertisement
Trending on Pharmacy Times
1
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
2
Beyond Prescription Volume: Measuring the Pharmacist’s Value
3
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
4
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
5